Liquid biopsy is useful in detecting tumor heterogeneity, particularly when diverse resistance mechanisms develop in different tumor sites, as reported in the case of an NSCLC with an EGFR exon 19del and T790M, which had a liver progression with an acquired CCDC6-RET fusion. This evidence concerns the gene CCDC6 and neoplasm.